2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Deci

James L Januzzi
Mikhail Kosiborod
Laurence S Sperling

Despite major therapeutic advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D) (1). Over that time, the prevalence of T2D has increased, while the excess risk of adverse CV events in patients with T2D (compared with patients without diabetes) has remained largely unchanged (2). Accordingly, the development of treatment strategies to improve CV outcomes in this vulnerable patient population remains a major priority.

Read More

Journal of the American College of Cardiology, ISSN: 1558-3597, Vol: 72, Issue: 24, Page: 3200-3223